Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative…
Fisiopatologia della cardiotossicità
-
-
Cancer therapy and cardiovascular risk: focus on bevacizumab Panagiota Economopoulou, Athanasios Kotsakis, Ioannis Kapiris, and Nikolaos Kentepozidis…
-
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors…
-
Cancer chemotherapy and cardiac arrhythmias: a review Drug Saf. 2015 Feb;38(2):129-52. doi: 10.1007/s40264-014-0258-4. Tamargo, J., Caballero,…
-
BOOK – Cardio-Oncology: from bench to bedside Abe, J.-I., Sood, A. K., Martin J Cardio-Oncology:…
-
Diagnosis and treatment of left ventricular dysfunction and heart failure in cancer patients A.R. Lyon,…
-
Updates in Anthracycline-Mediated Cardiotoxicity Nebigil CG, Désaubry L. Front Pharmacol. 2018 Nov 12;9:1262. doi: 10.3389/fphar.2018.01262. eCollection 2018.…
-
BOOK AIOM: Cardio-Oncologia 2018 – Progetto speciale cardio-oncologia 2018 Russo A, Barbieri E, Barni S,…
-
Cardiovascular Disease and Breast Cancer: Where These Entities Intersect Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores…
-
New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer Kenzik KM,…